

Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study

C. Madsen,¹ M. R. Clausen,¹ T. L. Plesner,² A. Pasanen,^{3,4} T. Kuismanen,^{3,4} H. H. Bentzen,¹ J. M. Jørgensen,¹ I. B. Sillesen,¹ B. M. Himmelstrup,⁵ D. Rønnow-Jessen,⁶ K. R. Jensen,⁷ A. M. Pettinger,⁸ M. Ludvigsen,^{1,9} S. Leppä,^{3,4} and F. A. d'Amore^{1,9}

¹Department of Hematology and ²Institute of Pathology, Aarhus University Hospital, Aarhus, Denmark; ³Department of Oncology, Helsinki University Hospital Comprehensive Cancer Centre, Helsinki, Finland; ⁴Research Program Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland; ⁵Department of Hematology, Roskilde Hospital, Roskilde, Denmark; ⁶Department of Hematology, Vejle Hospital, Vejle, Denmark; ⁷Department of Hematology, Aalborg University Hospital, Aalborg, Denmark; ⁸Health Sciences Research, Mayo Clinic, Rochester, MN; and ⁹Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

Key Points

- Patients who received R-chemo followed by MR had an improved 5-year PFS and OS independent of prognostic factors.
- A reduction of the risk of HT was observed among the MR patients of the training, but not of the validation, cohort.

The introduction of the anti-CD20 antibody rituximab in combination with chemotherapy (R-chemo) has improved the prognosis of patients with follicular lymphoma (FL). During the last decade, the addition of a maintenance treatment with rituximab (MR) after R-chemo has been tested with the hope of further improving the outcome of these patients. Using 2 independent population-based cohorts, we investigated the effect of up-front MR on time related end points as well as the risk of histological transformation (HT). FL patients were included if they: (1) completed first-line induction treatment with R-chemo, (2) were alive after induction treatment and eligible for MR, and (3) had no evidence of HT at this time point. The training cohort consisted of 733 Danish patients of whom 364 were consolidated with MR; 369 were not. Patients receiving MR more often had advanced clinical stage (90% vs 78%), high Follicular Lymphoma International Prognostic Index (FLIPI) score (64% vs 55%), and bone marrow infiltration (49% vs 40%). Those consolidated with MR had an improved 5-year overall survival (OS; 89% vs 81%; $P = .001$) and progression-free survival (PFS; 72% vs 60%; $P < .001$). In the training cohort, MR was associated with a reduction of HT risk ($P = .049$). Analyses of an independent validation cohort of 190 Finnish patients confirmed the favorable impact of MR on 5-year OS (89% vs 81%; $P = .046$) and PFS (70% vs 57%; $P = .005$) but did not find a reduced risk of HT. The present population-based data suggest that the outcome of patients with FL has improved after consolidation of R-chemo with MR.

Introduction

In western countries, follicular lymphoma (FL) is the second most common lymphoma entity after diffuse large B-cell lymphoma (DLBCL).¹⁻³ FL is characterized by an indolent and chronic clinical course and apart from truly localized low burden disease, it is still regarded as an incurable condition with a natural history of recurrent relapses and, in a fraction of cases, transformation to an aggressive histology (histological transformation [HT]).⁴⁻⁷ When it occurs, HT is often associated with an unfavorable prognosis.⁸⁻¹²

Some FL patients are initially managed with an expectant approach without immediate need for antineoplastic treatment. For those where a therapeutic intervention is indicated (eg, high tumor burden, systemic symptoms, etc), the addition of the CD20 antibody rituximab to chemotherapy (R-chemo) has had a favorable impact on the time to progression, survival, and possibly also transformation rates.^{7,13-18}

However, which induction regimen should be preferred is still debated. The most commonly used chemoimmunotherapy regimens are combinations of rituximab with either: cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP); cyclophosphamide, vincristine, and prednisone (R-CVP); or bendamustine (R-Benda).^{16,17,19}

During the last decade, maintenance with rituximab (MR) after initial chemoimmunotherapy has been introduced with the hopes of further improving outcome for patients with FL. Several prospective and retrospective studies have demonstrated a beneficial impact of MR on outcome.²⁰⁻²⁸ This has been particularly evident with regard to progression-free survival (PFS), as shown by large randomized trials such as the Primary Rituximab and Maintenance (PRIMA)²² and Eastern Cooperative Oncology Group (ECOG) 1496²⁷ performed in the frontline setting. On the other hand, whether MR induces a significant improvement of overall survival (OS) and a reduction of the HT risk is still questioned.²⁹⁻³¹

In the present Nordic collaborative study looking at population-based cohorts from Denmark and Finland, we investigated the effect of up-front MR on outcome and HT risk in FL patients managed with or without an intention-to-treat MR strategy.

Patients and methods

Training cohort

Patients diagnosed with histologically verified FL or DLBCL from 1990 to 2015 were identified through the National Danish Pathology Registry.^{32,33} Pathology reports were reviewed for patients diagnosed with both FL and DLBCL during the study period. HT was defined as a biopsy proven FL grade 1-3A followed by a FL grade 3B or a DLBCL histologically ascertained through a later biopsy. Subsequently, the identified patient cohort was cross-linked with the prospectively collected data of the Danish Lymphoma Registry (LYFO)^{34,35} and only patients with a full set of evaluable data covering pretherapeutic clinicopathological features, treatment parameters, and outcome end points at baseline and follow-up were included. From this population, patients were eligible to enter the final training cohort if meeting the following criteria: (1) FL diagnosis within the time period 2000-2015, (2) completed first-line induction treatment with R-chemo, (3) alive and with no evidence of relapse/progression nor HT according to an assessment performed at least 2 months after conclusion of the primary induction treatment.

Validation cohort

For validation, an independent population-based series of 190 patients with grade 1-3A FL treated at the Helsinki University Hospital Comprehensive Cancer Center between 2005 and 2015 were used. The patients were identified according to criteria corresponding to those used for the identification and end-point evaluation of the training cohort. This study was approved by the Danish Data Protection Agency and the National Committee on Health Research Ethics (no. 1-10-72-276-13) and done in accordance with the Declaration of Helsinki.

Rituximab maintenance

All patients completed a full course of R-chemo as first-line induction treatment. The decision to apply treatment-free follow-up or start MR was taken on a case-by-case basis at the discretion of the treating physician, also guided by national and international recommendations.

For both the training and the validation cohort, MR consisted of 375 mg/m² IV or subcutaneously given every second month for 2 years.

Response criteria

Pretherapeutic staging procedures were performed according to local guidelines and included diagnostic imaging with computed tomography or positron emission tomography-computed tomography scans, bone marrow biopsy (only repeated in patients with lymphoma infiltration at baseline), and ad hoc investigations in case of specific organ involvements. Treatment response was assessed according to the 1999 International Working Group criteria.³⁶

Statistical methods


Patient characteristics were compared using the Fisher's exact or Student *t* test. OS was defined from the date of initiation of first-line induction treatment to the date of death by any cause or censoring; PFS was calculated from the date of initiation of first-line induction treatment to the date of progression/relapse or censoring. Time to transformation (TTT) and transformation-free survival (TFS) were calculated from the date of initiation of first-line induction treatment to the date of biopsy proven HT. All time-related end points were estimated by the Kaplan-Meier method and compared by the log-rank test if the assumption of proportional hazards was fulfilled; otherwise, a pseudo value approach for comparing survival functions at a fixed time point was used.^{37,38} Factors of potential clinical relevance were tested in a multivariate analysis using either a Cox regression or a pseudo value approach.^{37,39} Risk estimates were expressed as hazard ratios (HRs) or risk differences (RDs) with 95% confidence intervals (CIs) at 5 years from first-line induction treatment. The risk of HT was evaluated in a competing risk model with death as a competing event, presented as cumulative incidence functions and compared using the model described by Pepe and Mori.⁴⁰⁻⁴² HT-associated risk estimates at fixed time points were calculated using the pseudo values approach and expressed as cumulative incidence proportions (CIPs) and relative risk (RR) with 95% CIs at 5 years.⁴⁰ All statistical analyses were performed using STATA (version IC 14; StataCorp, College Station, TX) or SPSS 22.0 (IBM, Armonk, NY).

Results

Training cohort

The training cohort consisted of 733 patients. All patients had completed their first-line rituximab-containing induction chemotherapy. Of the 733 patients, 364 received MR, whereas 369 did not. An algorithm describing how the training cohort was identified is shown in Figure 1. Pretherapeutic clinicopathological features and therapeutic background data of the training cohort are summarized in Table 1. The 2 treatment groups (no-MR vs MR) were comparable in terms of sex and age distribution, performance status and lactate dehydrogenase elevation. Conversely, patients receiving MR had more often disseminated disease (clinical stage III-IV; *P* < .001), a high risk profile (Follicular Lymphoma International Prognostic Index [FLIPI] intermediate/high; *P* < .001), multiple node involvement (*P* < .001), and bone marrow infiltration (*P* = .016). Of the 733 patients treated with rituximab-induction therapy, 286 (39%) received a doxorubicin-containing regimen (R-CHOP/CHOP-like) whereas 447 (61%) did not. Among the latter group, 347 (47%) were treated with R-CVP/CVP-like, 69 (9%) with R-Benda and 31 (4%) with a variety of other chemoimmunotherapy regimens. Doxorubicin-containing

Figure 1. Consort diagram of training cohort.



regimens were administered more often in patients that did not receive MR than in those who did (47% vs 31%; $P < .001$).

Outcome in the training cohort

The median follow-up was 4.7 years (0.2-14.0 years) for the entire cohort, 3.8 years (0.6-11.9 years), for patients consolidated with MR, and 5.7 years (0.2-14 years) for the patients who did not receive MR. The shorter median follow-up for MR patients was associated with a less frequent use of MR in the beginning of the study period.

Despite a more adverse risk profile, patients consolidated with MR had a significantly improved 5-year OS (89% vs 81%; $P = .001$), PFS (72% vs 60%; $P < .001$), and TFS (84% vs 76%; $P = .002$) (Figure 2; Table 2). This was true for both sexes (data not shown). Among patients with grade 3A histology, MR was administered to 40.2% ($n = 72$), whereas 59.8% ($n = 107$) did not receive it. In terms of impact, the PFS and OS values for no MR vs MR among grade 3A patients were in favor of MR: (1) PFS 62% (95% CI, 51-71) vs 73% (95% CI, 57-84) ($P = .043$) and (2) OS 80% (95% CI, 70-87) vs 90% (95% CI, 73-96) ($P = .039$), respectively.

When considering different induction therapies, no significant effect of MR consolidation on either OS (87% vs 81%; $P = .161$), PFS (67% vs 60%; $P = .183$), or TFS (81% vs 76%; $P = .260$) was found for patients treated with R-CVP/CVP-like as induction therapy (Figure 2; Table 2). On the other hand, the patients treated with R-CHOP/CHOP-like had a favorable effect

of MR on all outcome parameters, that is, OS (93% vs 81%; $P = .003$), PFS (77% vs 60%; $P = .004$), and TFS (88% vs 77%; $P = .021$). In the training cohort, the number of patients receiving R-Benda was low and no difference in outcome was detected between no MR and MR, probably due to insufficient statistical power.

Of the 733 patients representing the entire training cohort, 155 relapsed and 118 died. Upon relapse after MR or observation, 128 received salvage treatment consisting of R-chemotherapy ($n = 105$), rituximab only ($n = 15$), or chemotherapy only ($n = 8$). Overall, the fraction of patients receiving rituximab at first relapse was 80% in both the no MR and MR group. Twelve deaths (3%) were registered to have occurred among MR patients within a 2.5-year period from start of MR. Of these deaths, 2 (17%) were reported to be treatment-related.

In a multivariable adjusted analysis performed on the entire training cohort and adjusted for selected prognostic factors (FLIPI, use of anthracycline in the induction regimen, grade 3A histology, bulky disease, sex), MR significantly improved OS (RD, 8%; $P = .019$), PFS (RD, 15%; $P < .001$), and TFS (RD, 10%; $P = .007$) (Table 3). A high FLIPI score also predicted adverse outcome in term of OS (RD, -11%; $P = .014$) and PFS (RD, -14%; $P = .024$), but not TFS (RD, -8%; $P = .135$). In the subset of patients treated with doxorubicin-containing induction, MR still significantly improved OS (RD, 10%; $P = .049$), PFS (RD, 23%; $P < .001$) and TFS (RD, 12%; $P = .028$) after multivariate analysis. The same was not the case for FL histological grade 3A.

Table 1. Overview of demographic and outcome features in both the training and the validation cohort

Characteristic	Training cohort, n (%)				Validation cohort, n (%)			
	All, n = 733	-MR, n = 369	+MR, n = 364	P	All, n = 190	-MR, n = 103	+MR, n = 87	P
Sex								
Male	370 (50)	175 (47)	195 (54)		82 (43)	44 (43)	38 (44)	
Female	363 (50)	194 (53)	169 (46)	NS	108 (57)	59 (57)	49 (56)	NS
Age at FL diagnosis, y								
Median	61	61	62		61	62	60	
Range	24-87	24-86	30-87	NS	21-83	32-83	21-83	NS
Ann Arbor Stage								
I-II	117 (16)	82 (22)	35 (10)		29 (15)	16 (15)	13 (15)	
III-IV	611 (84)	284 (78)	327 (90)	<.001	161 (85)	87 (85)	74 (85)	NS
FLIPI								
Low	114 (16)	84 (24)	30 (8)		30 (16)	12 (12)	18 (21)	
Intermediate	173 (24)	75 (21)	98 (28)		56 (29)	31 (30)	25 (29)	
High	424 (60)	198(55)	226 (64)	<.001	104 (55)	60 (58)	44 (51)	NS
Nodal involvement ≥4	524 (71)	241 (65)	283 (78)	<.001	130 (68)	70 (68)	60 (69)	NS
Bulky disease	296 (48)	136 (45)	160 (51)	NS	N/A	N/A	N/A	N/A
B symptoms	265 (37)	127 (35)	138 (38)	NS	42 (22)	15 (15)	27 (31)	.008
Performance score ≥2	32 (4)	18 (5)	14 (4)	NS	29 (15)	19 (18)	10 (12)	NS
Bone marrow involvement	323 (44)	146 (40)	177 (49)	.016	N/A	N/A	N/A	N/A
Anemia	143 (20)	67 (18)	76 (21)	NS	27 (14)	13 (13)	14 (16)	NS
LDH elevation	242 (34)	120 (33)	122 (34)	NS	56 (30)	32 (31)	24 (28)	NS
FL histology								
FL NOS	22 (3)	7 (2)	15 (4)		2 (1)	1 (1)	1 (1)	
FL grade 1-2	532 (73)	255 (69)	277 (76)		152 (80)	82 (80)	70 (80)	
FL grade 3A	179 (24)	107 (29)	72 (20)	.005	36 (19)	20 (19)	16 (18)	NS
Induction therapy								
R-CHOP/CHOP-like	286 (39)	172(47)	114 (31)					
R-CVP/CVP-like	347 (47)	154 (41)	193 (53)		114 (60)	50 (49)	64 (74)	
R-Benda	69 (9)	18 (5)	51 (14)		8 (4)	2 (2)	6 (7)	
R-other chemotherapy	31 (4)	25 (7)	6 (2)	<.001	68 (36)	51 (49)	17 (19)	.001
Rituximab-containing induction therapy	733 (100)	369 (100)	364 (100)	NS	190 (100)	103 (100)	87 (100)	NS
Response status after induction therapy								
Chemosensitive (CR/PR)	703 (97)	345 (94)	358 (98)		183 (96)	99 (96)	84 (97)	
Nonchemosensitive (NC/PD)	19 (3)	15 (4)	4 (1)		7 (4)	11 (4)	9 (3)	
Missing	11 (1)	9 (2)	2 (1)	NS	0	0	0	NS

Bold values represent significant *P* values (*P* < .05).

CR, complete remission; NC, no change; NOS, not otherwise specified; NS, not significant; PD, progressive disease; PR, partial remission.

In patients treated without doxorubicin only a high FLIPI risk score was able to predict outcome, whereas MR treatment was uninformative (Table 3).

Impact of MR on risk of HT and TTT

Among the 733 patients in the training cohort, 60 transformed to an aggressive histology. Of these, 54 (90%) transformed to DLBCL and 6 (10%) to FL grade 3B. There was no difference in terms of transformation histology between no MR and MR patients. An overall reduction in the risk of transformation was observed for patients treated with MR within the training cohort

(*P* = .049; Figure 3). However when assessing the estimates at fixed time points this advantage was not significant (CIP at 5 years: 2.7 without MR vs 0.8 with MR; RR, 0.30; *P* = .069; Table 4). In terms of HT, the benefit of MR seemed more evident in patients who did not receive a doxorubicin-containing induction (Table 4; Figure 3), though the frequency of HT in CHOP/CHOP-like treated patients was overall low (6%; Table 4).

TTT was significantly shorter in patients that did neither receive doxorubicin-containing induction nor MR (2.6 years vs 1.3 years; *P* = .022). In these patients, the addition of MR improved TTT




Figure 2. Outcome by maintenance and type of induction treatment. OS (A), PFS (B), and TFS (C) by maintenance and type of induction treatment (training cohort). Time calculated from initiation of first-line induction treatment.

values up to a level comparable to that of R-CHOP/CHOP-like treated patients (Table 4). Interestingly, once histologically transformed, patients did not have different outcome regardless of prior MR or not (data not shown).

Validation cohort

To validate the impact of MR on outcome, we analyzed an independent Finnish population-based cohort of 190 FL patients treated with R-chemo. Of them, 87 received MR and 103 did not. The pretherapeutic clinicopathological features and therapeutic background data of the validation cohort are listed in Table 1. Apart from B symptoms, which were more frequent in the group of patients receiving MR, baseline characteristics were equally

distributed between the 2 treatment groups (no MR vs MR). However, R-CHOP was administered more often in patients that received MR than in those who did not (74% vs 49%; $P = .001$). The clinical outcomes according to treatment groups are shown in Table 2 and Figure 4. The patients consolidated with MR had a significantly better 5-year OS (89% vs 81%; $P = .046$) and PFS (70% vs 54%; $P = .004$), as compared with the patients who did not receive MR (Table 2; Figure 4). Although the risk of progression was reduced in the patients who received MR (HR, 0.487; 95% CI, 0.290-0.819; $P = .007$), no significant impact on the risk of HT was seen. In a multivariate analysis adjusted for FLIPI risk groups, and histological grade, a favorable prognostic impact of MR on PFS (HR, 0.470; 95% CI,

Table 2. Outcome according to treatment strategy for both training and validation cohort

	5-y OS (95% CI), %			5-y PFS (95% CI), %			5-y TFS (95% CI), %		
	-MR	+MR	P	-MR	+MR	P	-MR	+MR	P
Training cohort									
All	81 (76-85)	89 (84-93)	.001	60 (55-65)	72 (66-77)	<.001	76 (71-80)	84 (79-84)	.002
R-CHOP/CHOP-like*	81 (73-88)	93 (85-99)	.003	60 (52-69)	77 (66-89)	.004	77 (69-85)	88 (79-98)	.021
R-CVP/CVP-like*	81 (74-88)	87 (79-96)	NS	60 (51-68)	67 (57-78)	NS	76 (68-83)	81 (72-91)	NS
Validation cohort									
All	81 (69-88)	89 (77-95)	.046	54 (42-64)	70 (57-80)	.004	92 (82-96)	93 (82-98)	NS

Bold values represent significant P values (P < .05).

*Pseudo values approach, nonproportional hazards.

0.278-0.795; P = .005), and OS (HR, 0.406; 95% CI, 0.166-0.996; P = .049) was retained.

Discussion

In the present analysis of prospectively collected data from 2 large independent cohorts of FL patients, we found an outcome advantage for patients receiving up-front MR following R-chemo

induction. This advantage was not limited to PFS, but it also included OS in both the training and the validation cohort.

A number of previous prospective and retrospective studies have also demonstrated a beneficial impact of MR on outcome.^{21,22,24-28} This has been particularly evident with regard to PFS. The results of the large randomized PRIMA trial comparing MR with observation without further therapy following R-chemo induction, showed an

Table 3. Adjusted outcome analyses according to treatment strategy

Training cohort	Variable	RD for OS at 5 y, %			RD for PFS at 5 y, %			RD for TFS at 5 y, %		
		RD	95% CI	P	RD	95% CI	P	RD	95% CI	P
All	MR	8	1 to 15	.019	15	7 to 24	<.001	10	3 to 17	.007
	FLIPI									
	Low	—	—	—	—	—	—	—	—	—
	Intermediate	-1	-11 to 8	NS	4	-9 to 18	NS	2	-9 to 13	NS
	High	-11	-20 to -2	.016	-14	-26 to -2	.023	-8	-18 to 2	NS
	Bulk	-4	-10 to 3	NS	-10	-18 to -1	.025	-5	-12 to 2	NS
	FL grade 3A	-4	-12 to 4	NS	-3	-14 to 7	NS	-4	-13 to 4	NS
	+ Anthracycline	4	-3 to 11	NS	9	-1 to 18	NS	7	-1 to 15	NS
R-CHOP/CHOP-like	MR	10	1 to 20	.049	23	10 to 35	<.001	12	1 to 23	.028
	FLIPI									
	Low	—	—	—	—	—	—	—	—	—
	Intermediate	2	-13 to 17	NS	8	-11 to 27	NS	4	-13 to 20	NS
	High	-7	-20 to 7	NS	-18	-36 to -1	.048	-5	-20 to 10	NS
	Bulk	0	-11 to 10	NS	-7	-21 to 7	NS	-5	-17 to 6	NS
	FL grade 3A	-2	-12 to 8	NS	0	-13 to 14	NS	-5	-16 to 7	NS
	Female sex	-3	-13 to 8	NS	4	-9 to 17	NS	3	-8 to 14	NS
R-CVP/CVP-like	MR	7	-3 to 17	NS	11	-2 to 24	NS	10	-1 to 21	NS
	FLIPI									
	Low	—	—	—	—	—	—	—	—	—
	Intermediate	-2	-15 to 12	NS	5	-16 to 25	NS	1	-14 to 17	NS
	High	-16	-30 to -2	.025	-18	-37 to 1	NS	-14	-29 to 1	NS
	Bulk	-6	-16 to 3	NS	-11	-23 to 2	NS	-5	-16 to 5	NS
	FL grade 3A	-4	-18 to 11	NS	-8	-27 to 11	NS	-4	-20 to 11	NS
	Female sex	4	-6 to 13	NS	7	-6 to 20	NS	9	-2 to 20	NS

Pseudo values approach, nonproportional hazards. Bold values represent significant P values (P < .05).




Figure 3. Cumulative incidence of HT by maintenance and type of induction treatment (training cohort). All patients (A), CHOP/CHOP-like (B), and CVP/CVP-like (C). Time calculated from initiation of first-line induction treatment.

improved complete remission rate and PFS, but not OS in MR treated patients.²² Another trial testing MR after R-chemo induction in the front-line setting was performed in elderly (>60 years) FL patients treated with rituximab in combination with fludarabine, mitoxantrone and dexamethasone and followed by a short MR schedule of 4 bimonthly courses of rituximab. No PFS or OS advantage was found following MR as compared with observation only.²⁸ On the other hand, the ECOG 1496 trial demonstrated a superior PFS in MR-treated patients after frontline induction with R-void CVP given every third week for a total of 6 courses.²⁷ No concomitant OS prolongation was seen.

Several of the above-mentioned studies were included in a meta-analysis of individual patient data from 2315 FL patients enrolled in 7 randomized controlled trials of which 5 were conducted in the up-front setting.⁴³ This analysis, demonstrated an OS benefit of MR compared with no MR which was consistent for relapsed/refractory disease but more questionable in the up-front setting after rituximab-containing induction.

Retrospective registry-based reports have shown MR-associated outcome advantages with variable end points, such as PFS,^{24,26,44} OS^{24,25,45} and time-to-next-treatment.²⁶ Other studies have not confirmed these findings, identifying at best a trend toward better OS.^{26,46} Although, the general impression is that of a favorable impact of MR on outcome, the differences observed among these registry-based studies are probably due to heterogeneity in, for

example, definition of target populations (eg, age, local vs disseminated disease, etc), choice of end points, length of follow-up, event verification, etc. Also in our study, 1 of the major limitations was the imbalance between parameters such as FLIPI score, FL histological grade 3A, response status, and use of anthracyclines in the induction regimen, as this may complicate the interpretation of a possible MR impact on outcome. Therefore, we performed a multivariable analysis (Table 3) with the specific intent to adjust for at least some of these imbalances. The result of this analysis showed that the favorable impact of MR on outcome was retained in both cohorts.

Another important consideration when evaluating the clinical impact of MR is the type of induction therapy used to achieve remission. In fact, and maybe somehow surprisingly, the benefit of receiving MR was greatest in the subset of patients treated with R-CHOP/CHOP-like induction (see Table 2 and Figure 2). In these patients, significantly better PFS, OS and TFS values were observed. The same was not the case for patients treated with MR after R-CVP/CVP-like regimens. This difference between doxorubicin-containing and doxorubicin-void induction persisted also after multivariable adjustment for anthracycline-containing regimens.

On the other hand, 2 recent phase 3 trials have shown no advantage for R-anthracycline-based regimens compared with R-Benda in the frontline setting of indolent lymphomas, including FL.^{19,47} However, none of these trials addresses the question of subsequent MR consolidation and their follow-up is still early.

Table 4. Transformation data of the training cohort

Training cohort	Frequency of transformation, n (%)			Cumulative risk of transformation at 5 y (95% CI), %					Time to transformation, mean (95% CI), y			
	All	-MR	+MR	All	-MR	+MR	RR	P*	All	-MR	+MR	P*
All	60 (8)	37 (10)	23 (6)	1.7 (1.0-3.0)	2.7 (1.5-4.4)	0.8 (0.0-1.8)	0.30 (0.08-1.97)	.069	2.0 (1.6-2.5)	1.8 (1.3-2.3)	2.5 (1.8-3.4)	.138
R-CHOP/ CHOP-like	18 (6)	14 (8)	4 (4)	0.7 (0.2-2.8)	0.6 (0.0-1.7)	0.9 (0.0-2.6)	1.5 (0.09-24.0)	.771	2.5 (1.9-3.5)	2.6 (1.8-3.6)	2.5 (0.7-8.7)	.976
R-CVP/ CVP-like	36 (10)	18 (12)	18 (9)	2.3 (1.2-4.6)	4.5 (1.3-7.8)	0.5 (0.0-1.5)	0.11 (0.01-0.92)	.042	1.9 (1.4-2.5)	1.3 (0.9-2.1)	2.6 (1.8-3.8)	.022

Bold values represent significant *P* values (*P* < .05).

**P* value for testing difference between estimates of cumulative risk at 5 y.




Figure 4. OS, PFS, and TFS by maintenance and type of induction treatment (validation cohort). OS (A), PFS (B), and TFS (C). Time calculated from initiation of first-line induction treatment.

A similar observation of improved PFS and OS after R-CHOP induction followed by MR was reported by 2 retrospective registry analyses, 1 by Janikova et al from the Czech Lymphoma Study Group²⁵ and 1 by Cheah et al from the MD Anderson Cancer Center.²⁴ Compared with these reports, the present study has 2 important advantages: (1) a markedly larger cohort size (twofold to threefold) and (2) the presence of a validation cohort.

The fact that a number of prospective and retrospective studies seem to report an advantage in PFS rather than OS for FL patients treated with MR after front line induction may reflect the prolonged OS of FL patients in the rituximab-era. In the light of a lower number of events, there will be an inevitable need of large study populations and extensive length of follow-up in order to demonstrate significant OS differences. This need may justify, despite of their inherent limitations, a role for large population-based retrospective analyses, such as the present one.

With regard to HT, a trend toward a reduction of HT risk was observed in the training cohort, but not confirmed in the validation set. The role of MR on the risk of HT in FL patients has been investigated in previous studies. In the recent update of the PRIMA trial, no significant impact of MR on HT occurrence was observed. However, the trial was not originally designed and powered to address this end point and histological verification at disease progression was performed in only a limited number of patients resulting in a possible underestimation of HT frequency.²⁹ Recently, an analysis of prospectively collected registry data from the National LymphoCare Study demonstrated a significant impact of MR on the frequency of HT with a reduction from 13% to 9.2% (HR, 0.67; 95% CI, 0.46-0.97) compared with patients that did not receive MR.³⁰ Also, a retrospective population-based analysis from the British Columbia Cancer Center suggested that the introduction of chemoimmunotherapy reduced the incidence of HT and that this effect was particularly evident in those patients that received MR ($P = .003$).³¹

The maintenance modality has recently also been adopted in the context of novel CD20 targeting antibodies.^{48,49} The recent GALLIUM study randomized rituximab vs obinutuzumab maintenance in patients with previously untreated advanced-stage FL and

showed a PFS, but not OS, benefit in favor of obinutuzumab.⁴⁸ The trial design did not include an “observation-only” cohort and results are therefore difficult to interpret with regard to the MR versus no MR debate. However, testing maintenance with novel second-generation anti-CD20 antibodies will most certainly be helpful in further clarifying the role of antibody maintenance for improving OS in FL patients.

In conclusion, the role of MR as part of the first-line standard of care strategy in treatment requiring FL is still debated. The present study adds to the existing data by showing that, in 2 independent cohorts of FL patients, the use of MR leads to an improvement of not only PFS, but also OS.

Acknowledgments

The authors thank all doctors and hematological departments who have contributed to collection of data to the Danish Lymphoma Registry (LYFO).

This work was supported by Region Midtjyllands Forskningsfond, Aarhus University Research Foundation, The Karen Elise Jensen Foundation, Helsinki University Hospital, Juselius Foundation, Finnish Cancer Societies, and Academy of Finland. M.R.C. was supported by the Program for Clinical Research Infrastructure (PROCRIN), Medical Biometrics, Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.

Authorship

Contribution: C.M. and F.A.d'A. were responsible for study conception and design; C.M. and T.L.P. revised all pathology reports; C.M., M.R.C., A.M.P., S.L., and F.A.d'A. planned and performed data analysis; C.M., M.L., S.L., and F.A.d'A. drafted the manuscript; and all authors contributed to collection, assembly, and interpretation of data, and took part in revision and final approval of the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Francesco A. d'Amore, Department of Hematology, Aarhus University Hospital, Tage Hansens Gade 2, 8000 Aarhus, Denmark; e-mail: frandamo@rm.dk.

References

1. Sant M, Allemani C, Tereanu C, et al; HAEMACARE Working Group. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. *Blood*. 2010;116(19):3724-3734.
2. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. *Blood*. 2006;107(1):265-276.
3. Turner JJ, Morton LM, Linet MS, et al. InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. *Blood*. 2010;116(20):e90-e98.
4. Swerdlow SH; World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer; 2008.
5. Relander T, Johnson NA, Farinha P, Connors JM, Sehn LH, Gascoyne RD. Prognostic factors in follicular lymphoma. *J Clin Oncol*. 2010;28(17):2902-2913.
6. Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. *J Clin Oncol*. 2009;27(8):1202-1208.
7. Tan D, Horning SJ, Hoppe RT, et al. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. *Blood*. 2013;122(6):981-987.
8. Conconi A, Ponzio C, Lobetti-Bodoni C, et al. Incidence, risk factors and outcome of histological transformation in follicular lymphoma. *Br J Haematol*. 2012;157(2):188-196.
9. Bastion Y, Sebban C, Berger F, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. *J Clin Oncol*. 1997;15(4):1587-1594.
10. Wong E, Dickinson M. Transformation in follicular lymphoma: biology, prognosis, and therapeutic options. *Curr Oncol Rep*. 2012;14(5):424-432.
11. Link BK, Maurer MJ, Nowakowski GS, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. *J Clin Oncol*. 2013;31(26):3272-3278.
12. Montoto S, Davies AJ, Matthews J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. *J Clin Oncol*. 2007;25(17):2426-2433.
13. Guirguis HR, Cheung MC, Piliotis E, et al. Survival of patients with transformed lymphoma in the rituximab era. *Ann Hematol*. 2014;93(6):1007-1014.
14. Ban-Hoefen M, Vanderplas A, Crosby-Thompson AL, et al. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. *Br J Haematol*. 2013;163(4):487-495.
15. Alonso-Álvarez S, Magnano L, Alcoceba M, et al. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group. *Br J Haematol*. 2017;178(5):699-708.
16. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-grade lymphoma study group. *Blood*. 2005;106(12):3725-3732.
17. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. *J Clin Oncol*. 2008;26(28):4579-4586.
18. Czuczman MS, Weaver R, Alkuzweny B, Berfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. *J Clin Oncol*. 2004;22(23):4711-4716.
19. Rummel MJ, Niederle N, Maschmeyer G, et al; Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. *Lancet*. 2013;381(9873):1203-1210.
20. Ghilmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. *Blood*. 2004;103(12):4416-4423.
21. Taverna C, Martinelli G, Hitz F, et al. Rituximab maintenance for a maximum of 5 years after single-agent rituximab induction in follicular lymphoma: results of the randomized controlled phase III trial SAKK 35/03. *J Clin Oncol*. 2016;34(5):495-500.
22. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. *Lancet*. 2011;377(9759):42-51.
23. van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. *J Clin Oncol*. 2010;28(17):2853-2858.
24. Cheah CY, Chihara D, Ahmed M, et al. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. *Ann Oncol*. 2016;27(5):895-901.
25. Janikova A, Bortlicek Z, Camp R, et al. Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database. *Leuk Lymphoma*. 2016;57(5):1094-1103.
26. Nastoupil LJ, Sinha R, Byrtek M, et al. The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. *Cancer*. 2014;120(12):1830-1837.
27. Barta SK, Li H, Hochster HS, et al. Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: a trial of the ECOG-ACRIN Cancer Research Group (E1496). *Cancer*. 2016;122(19):2996-3004.

28. Vitolo U, Ladetto M, Boccomini C, et al. Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi. *J Clin Oncol*. 2013;31(27):3351-3359.
29. Sarkozy C, Trneny M, Xerri L, et al. Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial. *J Clin Oncol*. 2016;34(22):2575-2582.
30. Wagner-Johnston ND, Link BK, Byrtek M, et al. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). *Blood*. 2015;126(7):851-857.
31. Al-Tourah AJ, Sehn LH, Moccia AA, Gascoyne RD, Connors JM. Transformation of follicular lymphoma in the era of immuno-chemotherapy: a population-based study from British Columbia [abstract]. *J Clin Oncol*. 2012;30(suppl 15):8049.
32. Bjerregaard B, Larsen OB. The Danish pathology register. *Scand J Public Health*. 2011;39(suppl 7):72-74.
33. Erichsen R, Lash TL, Hamilton-Dutoit SJ, Bjerregaard B, Vyberg M, Pedersen L. Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank. *Clin Epidemiol*. 2010;2:51-56.
34. Arboe B, El-Galaly TC, Clausen MR, et al. The Danish National Lymphoma Registry: coverage and data quality. *PLoS One*. 2016;11(6):e0157999.
35. Arboe B, Josefsson P, Jørgensen J, et al. Danish National Lymphoma Registry. *Clin Epidemiol*. 2016;8:577-581.
36. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group [published correction appears in *J Clin Oncol*. 2000;18(11):2351]. *J Clin Oncol*. 1999;17(4):1244.
37. Kjaersgaard MI, Parner ET. Instrumental variable method for time-to-event data using a pseudo-observation approach. *Biometrics*. 2016;72(2):463-472.
38. Parner ET, Andersen PK. Regression analysis of censored data using pseudo-observations. *Stata J*. 2010;10(3):408-422.
39. Hansen SN, Andersen PK, Parner ET. Events per variable for risk differences and relative risks using pseudo-observations. *Lifetime Data Anal*. 2014;20(4):584-598.
40. Binder N, Gerds TA, Andersen PK. Pseudo-observations for competing risks with covariate dependent censoring. *Lifetime Data Anal*. 2014;20(2):303-315.
41. Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? *Stat Med*. 1993;12(8):737-751.
42. Pepe MS, Longton G, Pettinger M, Mori M, Fisher LD, Storb R. Summarizing data on survival, relapse, and chronic graft-versus-host disease after bone marrow transplantation: motivation for and description of new methods. *Br J Haematol*. 1993;83(4):602-607.
43. Vidal L, Gafter-Gvili A, Salles G, et al. Rituximab maintenance improves overall survival of patients with follicular lymphoma-individual patient data meta-analysis. *Eur J Cancer*. 2017;76:216-225.
44. Yared J, Kimball A, Baer MR, Bahrain H, Auerbach M. Rituximab maintenance therapy until progression after rituximab and chemotherapy induction in patients with follicular lymphoma. *Clin Lymphoma Myeloma Leuk*. 2013;13(3):253-257.
45. Vilmar A, Arboe B, Josefsson P, et al. Rituximab maintenance after first line immunochemotherapy improves overall survival in patients with follicular lymphoma [abstract]. *Blood*. 2016;128(22). Abstract 1781.
46. Bech RS, Nielsen KL, Larsen TS, et al. Real world data on rituximab maintenance therapy after frontline immunochemotherapy in grade 1-3a follicular lymphoma [published online ahead of print 23 May 2017]. *Br J Haematol*. doi:10.1111/bjh.14775.
47. Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. *Blood*. 2014;123(19):2944-2952.
48. Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. *N Engl J Med*. 2017;377(14):1331-1344.
49. Cheson BD, Chua N, Mayer J, et al. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study [published online ahead of print 27 March 2018]. *J Clin Oncol*. doi:10.1200/JCO.2017.76.3656.